Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection

Revealing tissue-specific SARS-CoV-2 infection and host responses using human stem cell derived lung and cerebral organoids

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera

The antigenic anatomy of SARS-CoV-2 receptor binding domain

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera

Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape

Assessing the influence of climate on wintertime SARS-CoV-2 outbreaks

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Reduction in mobility and COVID-19 transmission

Global absence and targeting of protective immune states in severe COVID-19

Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study

Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial

Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: A randomized clinical trial

Alzheimer Europe continues to develop and improve its Clinical Trials Watch (CTW), an innovative online resource providing up-to-date accessible information on clinical trials currently recruiting participants in a least one European country.

In late 2019, the European Brain Council (EBC) launched the development of the Shared European Brain Research Agenda (SEBRA).